Prognostication in thin cutaneous melanomas

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 12, 2010, Pages 1758-1763

  Gimotty, Phyllis A ^a,b   Guerry, Dupont ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER REGISTRY; CANCER STAGING; CELL PROLIFERATION; CLASSIFICATION; FEMALE; HUMAN; MALE; MELANOMA; METABOLISM; MORTALITY; PROGNOSIS; SKIN TUMOR; SURVIVAL RATE;

CELL PROLIFERATION; FEMALE; HUMANS; MALE; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SEER PROGRAM; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 78650445664     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin. 2000;50(4):215-236.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
3. US National Institutes of Health. Surveillance, Epidemiology and End Results (SEER) Program Limited-Use Data (1973-2006). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer SEER Statistics Branch. www.seer.cancer.gov. Released April 2009. Accessed April 15, 2009.
4. Gimotty PA, Botbyl J, Soong SJ, Guerry D. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2005;23(31):8065-8075.
5. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25(9):1129-1134.
6. Agnese DM, Abdessalam SF, Burak WE Jr, Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134(4):542-547.
7. National Comprehensive Cancer Network. Melanoma: clinical practice guidelines in oncology. Version 1. 2010. http://www.nccn.org/professionals/ physician-gls/PDF/melanoma.pdf. Accessed November 22, 2009.
8. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
9. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-3634.
10. Thomas JM. Prognostic false-positivity and cost-effectiveness in sentinel node biopsy in melanoma. Ann Surg Oncol. 2009;16(10):2961.
11. Clark WH Jr, Elder DE, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81(24):1893-1904.
12. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma: the Pigmented Lesion Group. Ann Intern Med. 1996;125(5):369-375.
13. Gimotty PA, Guerry D, Elder DE. Validation of prognostic models for melanoma. Am J Clin Pathol. 2002;118(4):489-491.
14. Bedrosian I, Faries MB, Guerry D, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7(4):262-267.
15. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22(18):3668-3676.
16. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12(6):449-458.
17. Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006;107(10):2436-2445.
18. Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13(4):533-541.
19. Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther. 2005;18(5):369-385.
20. Faries MB, Morton DL. Surgery and sentinel lymph node biopsy. Semin Oncol. 2007;34(6):498-508.
21. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370-2380.
22. Shaw HM, Scolyer RA, Thompson JF. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology. 2008;52(3):242-244.
23. Cochran AJ, Roberts A, Wen DR, et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours. Pathology. 2004;36(5):478-484.
24. Ariyan CE, Coit DG. Clinical aspects of sentinel lymph node biopsy in melanoma. Semin Diagn Pathol. 2008;25(2):86-94.
25. Glumac N, Hocevar M, Zadnik V, Snoj M. Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients. J Surg Oncol. 2008;98(1):46-48.
26. Elder DE, Murphy GF. Malignant tumors (melanomas and related lesions). In: Elder DE, Murphy GF, eds. Melanocytic Tumors of the Skin. Washington, DC: Armed Forces Institute of Pathology; 1991:158-159. Atlas of Tumor Pathology; 3rd series, fascicle 2.
27. Cochran AJ. Method of assessing prognosis in patients with malignant melanoma. Lancet. 1968;2(7577):1062-1064.
28. Gimotty PA, Van BP, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23(31):8048-8056.
29. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446(7132):153-158.
30. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-4346.
31. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
32. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9(17):6483-6488.
33. Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol. 2004;17(7):747-755.
34. Sondak VK, Messina JL. Current status of biomarkers for melanoma metastasis. IDrugs. 2006;9(9):627-631.
35. Sekulic A, Haluska P Jr, Miller AJ, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008;83(7):825-846.
36. Retsas S, Mastrangelo MJ. Reflecting on the 2001 American Joint Committee on Cancer staging system for melanoma. Semin Oncol. 2007;34(6):491-497.
37. Hoon DS, Kitago M, Kim J, et al. Molecular mechanisms of metastasis. Cancer Metastasis Rev. 2006;25(2):203-220.